Novo Nordisk celebrates 75-year commitment to diabetes research
- Details
- Category: Novo Nordisk
Novo Nordisk celebrates two milestone anniversaries, which demonstrates the company's long-term commitment to diabetes care and research. The day marks the 75-year anniversary of the Steno Diabetes Center and the 50-year anniversary of the Hagedorn Research Institute.
Taisho and Pfizer Sign a Letter of Intent for Taishoâs Schizophrenia Drug Candidate
- Details
- Category: Pfizer
Taisho Pharmaceutical Co., Ltd. [Headquarter: Toshima-ku, Tokyo, Japan, President: Akira Uehara] (hereinafter, Taisho) and Pfizer Inc. [Headquarter: New York, NY, USA, CEO: Jeffrey B. Kindler] (hereinafter, Pfizer) have concluded a letter of intent with regard to TS-032, a new schizophrenia drug candidate discovered by Taisho and currently in the pre-clinical stage. The letter of intent relates to a proposed license agreement regarding rights for development and commercialization of the substance outside Japan.
Tasigna® receives US approval providing new hope to chronic myeloid leukemia patients
- Details
- Category: Novartis
Tasigna® (nilotinib) has been approved in the US as a new anti-cancer therapy for certain patients with a life-threatening form of leukemia who are resistant or intolerant to prior treatment including Glivec® (imatinib)*, an established treatment standard and a leading Novartis medicine.
Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension
- Details
- Category: Product
Forest Laboratories, Inc. (NYSE: FRX) today announced the results of a double-blind, randomized, placebo-controlled clinical trial, published in the November 2007 issue of the Journal of Clinical Hypertension, which demonstrated that nebivolol significantly reduced sitting diastolic and systolic blood pressure used as monotherapy among African-American patients with stage I-II hypertension.
Nexavar® Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
- Details
- Category: Bayer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that the European Commission has granted marketing authorization to Nexavar® (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), or liver cancer. Nexavar, an oral anti-cancer drug, is the first and only approved systemic drug therapy for liver cancer and the only drug therapy shown to significantly improve overall survival in patients with the disease.
Nycomed signs definitive agreement to acquire Bradley Pharmaceuticals, Inc.
- Details
- Category: Nycomed
Nycomed today announced the entry into a definitive agreement to acquire Bradley Pharmaceuticals, Inc., a company focused on niche therapeutic markets in the USA. The acquisition will add further branded dermatologics to the PharmaDerm division of Nycomed US and will provide an enhanced platform for in-licensing and co-promotion of dermatology products. The transaction is subject to the receipt of Bradley shareholder approval and approval by competition authorities. It is expected to close in the first quarter of 2008.
Pfizer to Appeal German Court Decision in Lipitor Patent Case
- Details
- Category: Pfizer
Pfizer Inc said that the Federal Patent Court in Munich, Germany has revoked the companyâs patent covering atorvastatin calcium, the active ingredient in Lipitor. The patent at issue in the lawsuit (EP 409,281) expires in July 2010.
More Pharma News ...
- GSK reports third quarter EPS of 23.7p
- Bristol-Myers Squibb Company Reports Financial Results
- Bayer Issues Additional Guidance to Physicians on Trasylol®
- One-Year Results from the Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
- Abbott Named to Science Magazine's List of Top Employers
- Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent
- Novartis delivers record earnings in first nine months of 2007